$HRTX, The FY2016 Earnings Forecast for the H
Post# of 23071
(Total Views: 202)
Posted On: 02/18/2017 9:50:50 AM
$HRTX,
The FY2016 Earnings Forecast for the Heron Therapeutics, Inc. (HRTX) Issued By Jefferies Group
February 18, 2017 Kevin B. Atencio
The FY2016 Earnings Forecast for the Heron Therapeutics, Inc. (HRTX) Issued By Jefferies Group
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Jefferies Group cut their FY2016 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Thursday. Jefferies Group analyst B. Amin now expects that the firm will post earnings per share of ($4.14) for the year, down from their previous estimate of ($3.95). Jefferies Group has a “Buy” rating and a $29.00 price objective on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($0.82) EPS, FY2017 earnings at ($2.72) EPS, FY2020 earnings at $3.91 EPS and FY2021 earnings at $5.33 EPS.
A number of other equities analysts also recently weighed in on HRTX. Leerink Swann reaffirmed a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a research report on Sunday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $34.00 price objective on shares of Heron Therapeutics in a research note on Friday. Cowen and Company reiterated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research note on Sunday, December 11th. Zacks Investment Research cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Finally, Brean Capital initiated coverage on Heron Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Heron Therapeutics has an average rating of “Buy” and an average price target of $37.75.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 13.50 on Monday. The firm’s 50-day moving average is $14.54 and its 200-day moving average is $17.06. Heron Therapeutics has a 1-year low of $12.30 and a 1-year high of $25.84.
A number of large investors have recently bought and sold shares of HRTX. Wells Fargo & Company MN boosted its position in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the last quarter. BlackRock Group LTD boosted its position in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in Heron Therapeutics during the second quarter valued at $213,000. Highbridge Capital Management LLC purchased a new position in Heron Therapeutics during the third quarter valued at $266,000. Finally, BlackRock Advisors LLC boosted its position in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
The FY2016 Earnings Forecast for the Heron Therapeutics, Inc. (HRTX) Issued By Jefferies Group
February 18, 2017 Kevin B. Atencio
The FY2016 Earnings Forecast for the Heron Therapeutics, Inc. (HRTX) Issued By Jefferies Group
Heron Therapeutics, Inc. (NASDAQ:HRTX) – Jefferies Group cut their FY2016 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Thursday. Jefferies Group analyst B. Amin now expects that the firm will post earnings per share of ($4.14) for the year, down from their previous estimate of ($3.95). Jefferies Group has a “Buy” rating and a $29.00 price objective on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($0.82) EPS, FY2017 earnings at ($2.72) EPS, FY2020 earnings at $3.91 EPS and FY2021 earnings at $5.33 EPS.
A number of other equities analysts also recently weighed in on HRTX. Leerink Swann reaffirmed a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a research report on Sunday, October 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $34.00 price objective on shares of Heron Therapeutics in a research note on Friday. Cowen and Company reiterated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research note on Sunday, December 11th. Zacks Investment Research cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Finally, Brean Capital initiated coverage on Heron Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Heron Therapeutics has an average rating of “Buy” and an average price target of $37.75.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 13.50 on Monday. The firm’s 50-day moving average is $14.54 and its 200-day moving average is $17.06. Heron Therapeutics has a 1-year low of $12.30 and a 1-year high of $25.84.
A number of large investors have recently bought and sold shares of HRTX. Wells Fargo & Company MN boosted its position in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the last quarter. BlackRock Group LTD boosted its position in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in Heron Therapeutics during the second quarter valued at $213,000. Highbridge Capital Management LLC purchased a new position in Heron Therapeutics during the third quarter valued at $266,000. Finally, BlackRock Advisors LLC boosted its position in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'